Special Issue

New Approaches to Vaccine Development and Delivery

Message from the Guest Editor

The COVID-19 pandemic created an opportunity for innovation in the development, evaluation, and speed of vaccine development and evaluation. Contemporary strategies such as nucleic acid vaccines, developing vaccines based on whole cells, exploring new vaccine delivery methods, and creating shelf-stable formulas have made it possible to approach prophylactic and therapeutic vaccines in new ways. In this Special Issue, we will examine new advances in the field of vaccines and delivery systems that could help propel the field forward beyond its previous limits.

Guest Editor

Dr. Antonio Carlos de Freitas

Laboratory of Molecular Studies and Experimental Therapy, Department of Genetics, Federal University of Pernambuco, Recife, Brazil

Deadline for manuscript submissions

31 October 2025



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/198440

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

